Credit Suisse’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$219M Sell
422,240
-11,742
-3% -$5.84M 0.21% 86
2023
Q4
$205M Buy
433,982
+13,755
+3% +$6.36M 0.2% 91
2023
Q3
$183M Sell
420,227
-85,244
-17% -$38.7M 0.19% 98
2023
Q2
$225M Sell
505,471
-30,948
-6% -$14.3M 0.22% 84
2023
Q1
$247M Buy
536,419
+38,524
+8% +$18.3M 0.25% 70
2022
Q4
$255M Buy
497,895
+54,846
+12% +$27.8M 0.27% 68
2022
Q3
$201M Sell
443,049
-988
-0.2% -$473K 0.22% 82
2022
Q2
$214M Buy
444,037
+156,282
+54% +$77.3M 0.22% 77
2022
Q1
$141M Buy
287,755
+18,520
+7% +$8.47M 0.12% 170
2021
Q4
$125M Sell
269,235
-22,135
-8% -$9.31M 0.07% 306
2021
Q3
$109M Sell
291,370
-21,886
-7% -$8.32M 0.06% 345
2021
Q2
$120M Sell
313,256
-4,809
-2% -$1.84M 0.06% 326
2021
Q1
$114M Sell
318,065
-27,643
-8% -$8.89M 0.06% 361
2020
Q4
$111M Sell
345,708
-30,121
-8% -$9.24M 0.05% 377
2020
Q3
$101M Sell
375,829
-8,630
-2% -$2.32M 0.06% 341
2020
Q2
$101M Sell
384,459
-13,086
-3% -$3.49M 0.07% 277
2020
Q1
$90.3M Sell
397,545
-50,553
-11% -$13.8M 0.08% 249
2019
Q4
$135M Buy
448,098
+46,969
+12% +$12.9M 0.1% 201
2019
Q3
$96.3M Buy
401,129
+25,613
+7% +$7.02M 0.08% 235
2019
Q2
$106M Buy
375,516
+14,150
+4% +$3.87M 0.09% 211
2019
Q1
$104M Sell
361,366
-99,738
-22% -$28.8M 0.09% 211
2018
Q4
$121M Buy
461,104
+77,890
+20% +$21.4M 0.13% 152
2018
Q3
$105M Buy
383,214
+28,085
+8% +$7.29M 0.09% 205
2018
Q2
$84.5M Sell
355,129
-112,785
-24% -$26.1M 0.08% 225
2018
Q1
$103M Buy
467,914
+5,368
+1% +$1.26M 0.1% 201
2017
Q4
$104M Buy
462,546
+94,754
+26% +$20.2M 0.09% 210
2017
Q3
$69.8M Sell
367,792
-37,773
-9% -$7.19M 0.07% 310
2017
Q2
$76.3M Sell
405,565
-103,164
-20% -$18.5M 0.07% 253
2017
Q1
$84.1M Sell
508,729
-55,539
-10% -$8.83M 0.08% 256
2016
Q4
$81.1M Buy
564,268
+85,670
+18% +$11.5M 0.08% 254
2016
Q3
$60M Sell
478,598
-4,160
-0.9% -$537K 0.06% 363
2016
Q2
$63.4M Buy
482,758
+38,113
+9% +$5.21M 0.07% 278
2016
Q1
$61.8M Buy
444,645
+38,684
+10% +$5.17M 0.07% 274
2015
Q4
$56.6M Buy
405,961
+13,384
+3% +$1.84M 0.07% 326
2015
Q3
$55M Buy
392,577
+149,499
+62% +$22.5M 0.07% 330
2015
Q2
$39.9M Buy
+243,078
New +$38.8M 0.04% 523
2015
Q1
Sell
-687,499
Closed -$86.4M 4405
2014
Q4
$86.4M Sell
687,499
-29,896
-4% -$3.69M 0.08% 265
2014
Q3
$85.8M Sell
717,395
-6,343
-0.9% -$728K 0.07% 286
2014
Q2
$77.9M Buy
723,738
+19,904
+3% +$2.05M 0.06% 305
2014
Q1
$70.1M Sell
703,834
-2,015,678
-74% -$182M 0.07% 290
2013
Q4
$251M Buy
2,719,512
+2,148,084
+376% +$191M 0.23% 75
2013
Q3
$47.8M Sell
571,428
-83,448
-13% -$7.15M 0.05% 363
2013
Q2
$53.6M Buy
+654,876
New +$49M 0.05% 356

Other funds holding ELV

Credit Suisse's ELV Position: Q1 2024 in Review

Credit Suisse reduced its Elevance Health (ELV) stake by 2.7% in Q1 2024, selling an estimated $5.84M and leaving 422,240 shares worth $219M. The position accounts for 0.21% of the portfolio, ranked #86.

Credit Suisse first reported a position in ELV in Q2 2013 and has held it in 43 quarters since. The position peaked at $255M in Q4 2022. 1,666 funds tracked by Wall St. Rank hold ELV as of Q1 2024.

  • Credit Suisse held 422,240 shares of Elevance Health worth $219M as of Q1 2024.
  • Credit Suisse sold 11,742 Elevance Health shares in Q1 2024, an estimated $5.84M.
  • Elevance Health made up 0.21% of Credit Suisse's portfolio in Q1 2024, its #86 holding.
  • Credit Suisse first reported a position in Elevance Health in Q2 2013 and has held it in 43 quarters since.
  • Credit Suisse's Elevance Health position peaked at $255M in Q4 2022.
  • 1,666 funds tracked by Wall St. Rank held Elevance Health as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.